Drug Discovery@nature.com 30 November 2012

Advertisement 4 GETS YOU 10 Save 10% on any package of 4 targeting projects. Scientists from the same organization can combine their orders to achieve discounts. Learn more. TABLE OF CONTENTS 30 November 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement New Partnering Opportunities in Alzheimer's Disease! A comprehensive interactive dashboard from Relay Technology Management. Click here for more information on Alzheimer's partnering opportunities.   News Top GlaxoSmithKline opens the door on clinical data sharing doi:10.1038/nrd3907 Moves to release more data from clinical trials could provide unprecedented opportunities to understand disease biology and drug effects. Full Text Cyclin-dependent kinase inhibitors move into Phase III doi:10.1038/nrd3908 After more than a decade of clinical development for cancer and numerous failures, Phase III trials of cyclin-dependent kinase inhibitors are beginning. Full Text Deal watch: Merck invests in pioneering cytomegalovirus programme doi:10.1038/nrd3905 Merck has purchased AiCuris's human cytomegalovirus programme, including its lead compound letermovir, an oral CMV terminase complex inhibitor that has successfully completed Phase II trials. Full Text Trial watch: Phase III success for first-in-class pulmonary hypertension drug doi:10.1038/nrd3906 Data presented by Bayer for its oral soluble guanylyl cyclase stimulator riociguat has generated high hopes for the drug's potential in the treatment of pulmonary hypertension. Full Text Analysis Top Bringing macrocycles full circle doi:10.1038/scibx.2012.1176 At the recent SciBX summit on macrocycles, participants identified four areas of science in which work is needed to enable innovation and laid out a roadmap for progress. Full Text Factors influencing non-approval of new drugs in Europe doi:10.1038/nrd3894 This analysis looked at marketing applications at the EMA for new active substances, revealing the extent to which certain underlying factors were associated with failure to be approved. Full Text Research Highlights Top Drug screening: A MuSIC-al way to identify drug pairs doi:10.1038/nrd3898 Researchers have a new method to identify synergistic drug pairs and new targets for the potential treatment of HIV. The method could be applicable to other therapeutic areas where combinations of drugs might offer improved benefits. Full Text Analgesics: Deadly snake venom for pain relief? doi:10.1038/nrd3897 Proteins from snake venom function as potent painkillers with a novel mechanism of action. They could be useful tools for dissecting pain pathways, as well as having potential therapeutic value themselves. Full Text Neurodegenerative diseases: Novel route to neuroprotection doi:10.1038/nrd3899 Compounds from a series based on P7C3 — an aminopropyl carbazole with neurogenic properties — have therapeutic effects in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Full Text Research & Reviews Top Protein kinase C, an elusive therapeutic target? doi:10.1038/nrd3871 This Review looks at the efforts, challenges and opportunities for the protein kinase C family, which have been a major focus of drug discovery efforts. Full Text Tankyrase-targeted therapeutics: expanding opportunities in the PARP family doi:10.1038/nrd3868 This Review focuses on the biology of tankyrases and the discovery of tankyrase-specific inhibitors. It also considers the challenges that lie ahead for the clinical development of PARP family inhibitors in general. Full Text Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline doi:10.1038/nm.2965 New research shows that inhibition of IL-12 and IL-23 signaling reduces plaque load and improves cognitive deficits in mouse models of Alzheimer's disease. The researchers suggest that this pathway may be targeted therapeutically. Full Text Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis doi:10.1038/nbt.2434 Researchers have shown that microparticles bearing encephalitogenic peptides induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis, preventing the onset and modifying the course of the disease. Full Text Drug Discovery JOBS of the week PhD Position: Functionalized Inorganic Materials for Water Remediation and Drug Delivery University of Southern Denmark, Department of Physics, Chemistry and Pharmacy Drug Discovery for Helminths Aroian Group, University of California, San Diego Senior Medical Director, Head of Global Drug Safety Medicine TA Group Oncology (m / f) Merck Group Director Research and Drug Development Children's Tumor Foundation Laboratory Head Drug Metabolism within Early and Investigative Drug Disposition and Safety (eiDDS) F. Hoffmann-La Roche AG More Science jobs from Drug Discovery EVENT The Drug Development Process - From Discovery to Commercialization 30.01.-01.02.13 PA, US More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.